Across TCGA pan-cancer cohorts, ZNF267 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZNF267 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ZNF267 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF267 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.
OV, ESCA, and SKCM are the cancer types where ZNF267 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.